A new specialized lab, office and collaboration space for over 100 life science and health technology professionals, entrepreneurs, and researchers was recently announced for The Campus, Cherrywood in South Dublin, Ireland.
bluebird bio has signed a long-term lease for a 61,000 square foot facility at Assembly Row, Greater Boston: saying the new headquarters has been designed to reflect modern ways of working and deliver significant cost savings.
Lonza has been investing in developing exosome manufacturing and characterization technologies for the past five years, and this week it ramped up its focus on that category by acquiring two sites.
During CPhI Worldwide, leaders from two organizations will outline how CM is taking off, potential benefits, and how to clear common obstacles to adoption.
Rentschler Biopharma and XL-protein have teamed up on the manufacture of what they say is a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I) that may open better treatment options for patients suffering from inflammation, chronic...
Biolife Solutions and its subsidiary SciSafe have opened a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, located next to Schiphol Airport.
Absci Corporation says its newly opened campus in Vancouver, Washington, in the US, expands its ability to accelerate discovery and development of biologic drugs.
Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing: with its sterile manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
Locus Biosciences has entered a credit facility of up to US$25m with Hercules Capital, which it says will support the expansion of its precision engineered bacteriophage discovery platform engine and in-house manufacturing capacity.
Touchlight, a synthetic DNA producer, says it has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK.
Aceto expands GMP product lines for biopharmaceutical and vaccine manufacturing with acquisition of A&C Bio Buffer, growing its manufacturing footprint and strengthening its presence in Europe.
Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.
Boehringer Ingelheim has inaugurated a state-of-the-art biopharmaceutical production facility in Vienna, Austria: representing the single largest investment in the company’s history.
A probe has identified 'human error’ at the Spanish contract development and manufacturing organization, Rovi, as the reason for the presence of metal contaminants in Moderna COVID-19 vaccine doses, leading to Japanese authorities withdrawing 1.6...
VGXI, Inc, a provider of plasmid DNA manufacturing and development services, says multiple construction milestones have been reached for its new headquarters and manufacturing facility in Texas.
Moderna is investing in a 462,000 square foot building in Cambridge, Massachusetts, to create a purpose-built space for scientific research and development labs.
The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.
Fujifilm Irvine Scientific Inc has started the commissioning phase of its new 250,000 square feet (22,800 square meter) cell culture media manufacturing facility in Tilburg, the Netherlands; the site joins existing plants in the US and Japan.
Takeda has received approval from Japan’s ministry of health to manufacture and market its stem cell therapy, Alofisel, for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease (CD).
Synthetic DNA vector producer, Touchlight, has announced the extension of its fundraising round to a current aggregate total of US$125m (£92m). The financing was led by Bridford Investments Limited and Novator Partners.
AGC Biologics is expanding its Heidelberg facility to create new capacity for messenger RNA (mRNA) projects, and to boost its plasmid-DNA (pDNA) manufacturing capabilities.
Cytiva, in collaboration with China's Wego Pharmaceutical Co Ltd, is expanding manufacturing capacity for bioprocessing single-use consumables in China.
French innovator, TreeFrog Therapeutics, which is focused on developing affordable stem cell-derived cell therapies, has just closed a US$75m (€64M) Series B financing round, bringing its total funding to date to US$83m (€70M).
CureVac is streamlining its external European manufacturing network for its mRNA product pipeline; having reassessed demand for its first-generation COVID-19 vaccine candidate.
Vaccitech has signed a lease for 31,000 sq. ft at Harwell Science and Innovation Campus in the UK, fitting out the facility with a state-of-the art wet laboratory and offices.
Catalent sees COVID-19 vaccines being an 'enduring and sustainable' revenue stream for the company, particularly with the advent of boosters, and the fact that developing countries, to date, have very low vaccination rates.
Seattle-based Umoja Biopharma, a company looking to reprogram immune cells in-vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, has started work on its new development and manufacturing facility...
The European Medicines Agency’s human medicines committee (EMA CHMP) has this week approved additional manufacturing capacity for Pfizer/BioNTech and Moderna COVID-19 vaccines.
Sweden’s Biotage says its expanded facility in the UK will allow it to triple its production capacity for equipment crucial in the supply chain for the production of mRNA vaccines, and thus eliminating a bottleneck for COVID-19 vaccines.
Earlier this month, Rentschler Biopharma, a contract development and manufacturing organization (CDMO), announced that it had broken ground on its new production facility, adjacent to its existing site in Milford, Massachusetts, in the greater Boston...
VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process....
